Apogee Therapeutics, Inc.
APGE
$43.84
$1.984.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.25M | 49.01M | 41.55M | 35.82M | 29.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 241.79M | 216.87M | 178.14M | 143.76M | 118.53M |
| Operating Income | -241.79M | -216.87M | -178.14M | -143.76M | -118.53M |
| Income Before Tax | -205.29M | -182.13M | -146.66M | -118.49M | -103.55M |
| Income Tax Expenses | 101.00K | 18.00K | -- | -- | -- |
| Earnings from Continuing Operations | -205.39 | -182.15 | -146.66 | -118.49 | -103.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -205.39M | -182.15M | -146.66M | -118.49M | -103.55M |
| EBIT | -241.79M | -216.87M | -178.14M | -143.76M | -118.53M |
| EBITDA | -241.42M | -216.68M | -140.88M | -82.24M | -38.15M |
| EPS Basic | -3.59 | -3.28 | -2.76 | -2.40 | -5.58 |
| Normalized Basic EPS | -2.24 | -2.05 | -1.72 | -1.50 | -3.49 |
| EPS Diluted | -3.59 | -3.28 | -2.76 | -2.40 | -5.58 |
| Normalized Diluted EPS | -2.24 | -2.05 | -1.72 | -1.50 | -3.49 |
| Average Basic Shares Outstanding | 228.76M | 220.75M | 211.89M | 196.33M | 144.81M |
| Average Diluted Shares Outstanding | 228.76M | 220.75M | 211.89M | 196.33M | 144.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |